ES2391525T3 - Glucanos y glucopéptidos de Campylobacter - Google Patents

Glucanos y glucopéptidos de Campylobacter Download PDF

Info

Publication number
ES2391525T3
ES2391525T3 ES03766087T ES03766087T ES2391525T3 ES 2391525 T3 ES2391525 T3 ES 2391525T3 ES 03766087 T ES03766087 T ES 03766087T ES 03766087 T ES03766087 T ES 03766087T ES 2391525 T3 ES2391525 T3 ES 2391525T3
Authority
ES
Spain
Prior art keywords
antibody
campylobacter
antigen binding
binding fragment
cattle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03766087T
Other languages
English (en)
Spanish (es)
Inventor
Noel M. Young
Jean-Robert Brisson
John Francis Kelly
David C. Watson
Christine M. Szymanski
Harold C. Jarrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council Canada
Original Assignee
National Research Council Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council Canada filed Critical National Research Council Canada
Application granted granted Critical
Publication of ES2391525T3 publication Critical patent/ES2391525T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Feed For Specific Animals (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Fodder In General (AREA)
ES03766087T 2002-08-01 2003-07-30 Glucanos y glucopéptidos de Campylobacter Expired - Lifetime ES2391525T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39973502P 2002-08-01 2002-08-01
US399735P 2002-08-01
PCT/CA2003/001156 WO2004013151A2 (en) 2002-08-01 2003-07-30 Campylobacter glycans and glycopeptides

Publications (1)

Publication Number Publication Date
ES2391525T3 true ES2391525T3 (es) 2012-11-27

Family

ID=31495764

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03766087T Expired - Lifetime ES2391525T3 (es) 2002-08-01 2003-07-30 Glucanos y glucopéptidos de Campylobacter

Country Status (9)

Country Link
US (1) US7598354B2 (enExample)
EP (1) EP1527080B1 (enExample)
JP (1) JP4718174B2 (enExample)
CN (1) CN1671722A (enExample)
AU (1) AU2003254665C1 (enExample)
BR (1) BR0312896A (enExample)
CA (1) CA2494223C (enExample)
ES (1) ES2391525T3 (enExample)
WO (1) WO2004013151A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
AU2002952121A0 (en) * 2002-10-17 2002-10-31 Alchemia Limited Novel carbohydrate based anti-bacterials
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
ES2535084T3 (es) * 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
WO2009089154A2 (en) 2008-01-03 2009-07-16 Cornell Research Foundation, Inc. Glycosylated protein expression in prokaryotes
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
SI2257307T1 (sl) 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
CN102365359B (zh) * 2009-03-27 2014-10-29 瑞士联邦苏黎世技术大学 呈递空肠弯曲杆菌n-聚糖或其衍生物的肠沙门氏菌
NO2501406T3 (enExample) 2009-11-19 2018-05-19
CA2789505C (en) 2010-02-11 2017-12-05 The Governors Of The University Of Alberta N-linked glycan compounds
EP2561085B1 (en) * 2010-04-20 2019-08-14 National Research Council of Canada Cell-based production of nonulosonates
WO2011138361A1 (en) 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
US9308246B2 (en) 2010-05-28 2016-04-12 The United States Of America As Represented By The Secretary Of The Navy Capsule composition for use as immunogen against Campylobacter jejuni
JP6135046B2 (ja) * 2012-04-20 2017-05-31 株式会社島津製作所 糖ペプチドの質量分析法
CA2907795C (en) 2013-04-05 2023-09-05 The Governors Of The University Of Alberta Campylobacter vaccine
ES2755042T3 (es) * 2015-01-26 2020-04-21 Cadena Bio Inc Composiciones de oligosacáridos para el uso como alimento para animales y sus métodos para producirlas
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
CN111491662A (zh) * 2017-12-19 2020-08-04 阿尔伯塔大学理事会 产气荚膜梭菌表面聚糖及其应用
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
WO2019204346A1 (en) 2018-04-16 2019-10-24 Northwestern University METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELLLYSATES
WO2020072127A2 (en) 2018-08-03 2020-04-09 Northwestern University On demand, portable, cell-free molecular sensing platform
EP3908669A4 (en) 2019-01-11 2023-05-03 Northwestern University SYNTHESIS OF BIOCONJUGATED VACCINES IN PROKARYOT CELL LYSATE
US12325884B2 (en) 2019-03-04 2025-06-10 Northwestern University Riboswitch-based fluoride sensing in cell-free extract
US12226410B2 (en) 2019-10-18 2025-02-18 Northwestern University Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
WO2021081485A1 (en) 2019-10-25 2021-04-29 Northwestern University Cell-free extract preparation protocol for enrichment of membrane vesicles and increased glycoprotein yields
WO2022256920A1 (en) * 2021-06-07 2022-12-15 The University Of British Columbia Acholetin biopolymers and methods for enzymatic synthesis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5200344A (en) * 1990-11-13 1993-04-06 Blaser Martin J Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens
JPH09502604A (ja) * 1993-08-27 1997-03-18 エンテリック リサーチ ラボラトリーズ インコーポレイテッド Ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉ抗原、並びにそれらの製造及び利用
US5882902A (en) * 1994-09-06 1999-03-16 Bioflexin Ab Amino acid conjugate
US5840547A (en) * 1995-01-05 1998-11-24 Ramot University Authority For Applied Research & Indfustrial Development Ltd. Bioemulsifiers
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
US6699705B2 (en) * 1999-02-01 2004-03-02 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
AU3513500A (en) * 1999-03-05 2000-09-21 Trustees Of Tufts College Emulsan and emulsan analogs immunization formulations and use
US6512014B2 (en) * 2000-12-13 2003-01-28 Ramot University Authority For Applied Research And Industrial Development Limited Compositions containing bioemulsifiers and a method for their preparation
EP2292273A3 (en) * 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
CA2623400C (en) * 2005-09-21 2015-04-07 Patricia Guerry Immunogenic capsule composition for use as a vaccine component against campylobacter jejuni

Also Published As

Publication number Publication date
EP1527080B1 (en) 2012-06-20
AU2003254665A1 (en) 2004-02-23
WO2004013151A2 (en) 2004-02-12
CA2494223A1 (en) 2004-02-12
JP4718174B2 (ja) 2011-07-06
US20060165728A1 (en) 2006-07-27
WO2004013151A3 (en) 2004-07-01
CN1671722A (zh) 2005-09-21
JP2005534752A (ja) 2005-11-17
US7598354B2 (en) 2009-10-06
CA2494223C (en) 2012-10-02
AU2003254665C1 (en) 2010-08-19
EP1527080A2 (en) 2005-05-04
AU2003254665B2 (en) 2010-01-28
BR0312896A (pt) 2005-06-14

Similar Documents

Publication Publication Date Title
US7598354B2 (en) Campylobacter glycans and glycopeptides
JP7370391B2 (ja) 大腸菌ｏ抗原多糖のバイオコンジュゲート、その製造方法およびその使用方法
Johnson et al. Designing a new antifungal glycoconjugate vaccine
EP3942028B9 (en) Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
Keenan et al. Alterations in Helicobacter pylori outer membrane and outer membrane vesicle-associated lipopolysaccharides under iron-limiting growth conditions
US20160136285A1 (en) An isolated immunogenic bacterial antigen and its use in the prevention and treatment of infections caused by gram-negative bacteria
Altman et al. Design and immunological properties of Helicobacter pylori glycoconjugates based on a truncated lipopolysaccharide lacking Lewis antigen and comprising an α-1, 6-glucan chain
Kohout et al. Semisynthetic Glycoconjugates as potential vaccine candidates against haemophilus influenzae type a
ES2535543T3 (es) Compuestos de glicano N-enlazado
Monteiro et al. Synthesis and immunogenicity of a Helicobacter pylori lipopolysaccharide-based conjugate
Midwinter et al. Characterization of an antigenic oligosaccharide from Leptospira interrogans serovar pomona and its role in immunity
ES2525122T3 (es) Antígeno de Enterococcus faecalis y/o Enterococcus faecium
CA2565247A1 (en) Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
Xiao et al. Antigenicity evaluation of synthetic α-(1, 3)-linked D, D-heptoglycan of Helicobacter pylori serotype O6 lipopolysaccharide
Yang et al. Reducing the endotoxic activity or enhancing the vaccine immunogenicity by altering the length of lipid A acyl chain in Salmonella
Vinogradov et al. The structure and biological characteristics of the Spirochaeta aurantia outer membrane glycolipid LGLB
HK40101412A (en) Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
HK40058952A (en) Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
HK40058952B (en) Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
EA046636B1 (ru) Способы получения биоконъюгатов полисахаридных о-антигенов e. coli, их композиции и способы их применения
Mehta Syntheses and antigenic analyses of oligosaccharides derived from Bacillus anthracis, Burkholderia pseudomallei and Burkholderia mallei
PL229194B1 (pl) Neoglikokoniugat oligocukru Escherichia coli R1 LOS i toksoidu Clostridium difficile oraz jego zastosowanie w szczepionkach przeciwbakteryjnych